siRNA targeting Livin decreases tumor in a xenograft model for colon cancer

Bo-Young Oh, Ryung-Ah Lee, Kwang Ho Kim

ABSTRACT

AIM: To evaluate the effect of silencing Livin gene expression with siRNA to apoptosis and proliferation in a colon cancer cell line.

METHODS: To investigate the anticancer effect of silencing Livin gene expression, we established an siRNA transfected cell line using the HCT116 colon cancer cell line. After confirming the successful transfection, MTT assay, flow cytometry and annexin V staining were employed to evaluate the antiapoptotic effect. To confirm the in vivo effect of Livin-siRNA, different doses of Livin-siRNA were injected into xenografted tumors in BALB/c nude mice model.

RESULTS: Livin expression was dramatically decreased after siRNA transfection, especially at 25 μmol/L of siRNA, but this suppression was not dose-dependent. The cell count at 18 h after transfection was significantly reduced as compared with controls (P < 0.01), but tended not to decrease proportionally depending on transfected dose or time. MTT assay revealed that silencing the Livin gene suppressed cellular proliferation at 18 h after transfection (P = 0.04); however, the inhibitory effect disappeared thereafter. Also, there was no significant difference in cellular proliferation depending on siRNA dose. The rate of apoptosis also increased with silencing of the Livin gene. In vivo, the tumor size significantly decreased after Livin-siRNA injection at 20 μmol/L concentration (P = 0.03). There were no significant body weight changes of mice after siRNA injection. Histologic examination revealed no significant toxic reaction in kidney, liver and brain of mice.

CONCLUSION: siRNA-mediated downregulation of Livin expression can induce apoptosis in colon cancer in vitro and in vivo, which suggests the possibility of new cancer therapeutics using siRNA.

INTRODUCTION

Colon cancer is one of the most common malignancies worldwide and has shown increased incidence, especially in developing countries [1]. Until recently, a major treatment strategy has been surgical resection that shows good outcome over other treatments. With the activation of a screen-
ing program, early cancer, less than stage I, is curable with only surgical treatment. But the treatment results for metastatic disease are still unsatisfactory with surgery alone. In these cases, clinicians consider other treatment options such as chemotherapeutic agents and targeted agents. Recently, development of techniques in manipulation of nucleic acids makes gene therapy possible to adopt in cancer therapy.

RNA interference (RNAi) is a fundamental protective process in eukaryotic cells including invertebrates and vertebrates, which is able to block harmful signal by targeting complementary mRNA and cleaving thereof\(^2\). Small interfering RNA (siRNA) is fragments from double-stranded RNA by the enzyme Dicer\(^3,4\). The natural role of RNAi is supposed to be a defense mechanism against some viral infection or deleterious genomic instability. This special mechanism has been of great interest recently as siRNA targeting small genes are easily manufactured and applied to major clinical problems such as cancer, asthma, inflammatory disease and infection\(^5\). This methodology is becoming a powerful tool for new drug development in such areas and is replacing the techniques of using antisense oligonucleotide and ribozymes\(^6,7\).

Livin, a 280 amino acid protein and a member of the mammalian type of inhibitor of apoptosis (IAP), are well-conserved proteins across the species. It has a single baculovirus IAP repeat (BIR) domain and a COOH-terminal RING domain and is located predominantly in the nucleus and a filamentous pattern of cytoplasm\(^8\). The Livin gene spans 46 kb and is located on chromosome 20 at band q13\(^9\). The major function of Livin is an inhibition of apoptosis by binding to caspase 3, caspase 7 and caspase 9 and also in inhibition of proteolytic processes of caspase 9\(^9,10\). Its overexpression protects cells from various proapoptotic stimuli.

The expression of Livin, similar to expression of Survivin, is rarely detected in normal adult tissues but exists abundantly in cancerous tissues and transformed cells\(^10\). The overexpression of Livin protein has been reported in colorectal cancer, leukemia, hepatocellular carcinoma, and melanoma\(^11\). Recently, major attention has been focused on the IAP family, especially Survivin and Livin, as they are easy to handle in the genetic field due to their small size. Moreover, the lack of expression in normal adult tissues of Livin is a very attractive characteristic in cancer therapy\(^11\).

In this study, we used siRNA targeting to Livin transfection into the HCT116 colon cancer cell line to confirm the antitumor effect and blockade of Livin gene and performed an additional in vivo study using BALB/c nude mice xenografts to determine the direct tumor regression effect of Livin silencing with siRNA. These results suggested that Livin is an effective target for colorectal cancer treatment using siRNA technique.

**MATERIALS AND METHODS**

**Materials**

Cell culture—The HCT116 colon cancer cell line, purchased from Korean cell line bank, was grown in RPMI1640 medium (Life Technologies, Inc., Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Life Technologies, Inc.), penicillin (100 U/mL) and streptomycin (100 g/mL). Cells were maintained at 37°C in a humidified atmosphere of 50 mL/L CO\(_2\).

**RT-PCR procedure**

Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA). The method for extracting total RNA was according to the manufacturer's protocol. RNA samples were quantified at 260 nm using spectrophotometry. One μg of total RNA was reacted for 15 min at 42°C using the Promega’s Reverse Transcription System (Promega Corp., Madison, WI), reacted for 5 min at 95°C, and cDNA was obtained. For polymerase chain reaction (PCR), cDNA (3 μL) was obtained by reverse transcription, 0.1 μmol primers, 1.25 μL GoTaq DNA polymerase, 0.2 mmol/L deoxynucleotide triphosphate (dNTP), 1 Go Taq reaction buffer and each primer was added, and DNA was amplified by performing PCR with primer of Livin; forward, 5-GTCAGTTCTTG-GTCCGGTGCAA-3; reverse, 5-GGGCACATTCTAGCAGGACCTC-3. Electrophoresis of PCR products was performed on 1.5% agarose gel and examined by staining with ethidium bromide. By measuring the brightness of bands using a densitometer, their amount was quantified using the value of β-actin as the standard value.

**siRNA design and preparation**

Synthetic 21-nt RNAs were purchased from Dharmacon Research (Lafayette, CO; in deprotected, desalted, and annealed form.). We used 4 primers for silencing the Livin gene to improve the blocking efficiency. The target sequences of Livin for production of siRNA were 5-GAGAGAAGGTCAGGTCAGTGCTGA-3, 5-GGAAGAACCGGAAGAGGCA-3, 5- GCTCTGAGGAGTTCCGTCT-3 and 5-GCTCTGAGGAGTTCCGTCTTT-3. The nonspecific control siRNA duplex was also purchased from Dharmacon Research.

Briefly, centrifuging tubes containing siRNA to ensure that the siRNA pellet was collected at the bottom of the tube. Resuspended siRNA to a convenient stock concentration with 1X siRNA buffer (Dharmacon, Inc., Lafayette, CO). After placing the solution on a shaker for 30 min at room temperature, the concentration of siRNA was verified using UV spectrophotometry at 260 nm.

HCT116 cells were diluted in fresh media without antibiotics and transferred to six-well plates (1 × 10\(^5\) cells/well) 24 h before transfection and maintained at 37°C in a humidified atmosphere of 50 mL/L CO\(_2\). HCT116 cells grown to a confluence of 40%-50% were transfected with siRNA using Lipofectamine 2000 (Life Technologies, Inc.), penicillin (100 U/mL) and streptomycin (100 g/mL). Cells were maintained at 37°C in a humidified atmosphere of 50 mL/L CO\(_2\).

**MTT assay**

Cell viability was examined by routine 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
HCT116 cells ($1 \times 10^6$) were planted in 96-well plates with RPMI1640 in a final volume of 500 μL. On the following day, cells were treated with increasing concentration of siRNA and cultured for 48 h, then cell proliferation was assessed by MTT assay. Following incubation at 37°C for 3 h, the reaction was stopped by the addition of 150 μL DMSO. After the crystal dissolved, the absorbency of the samples was determined at 492 nm.

**Cell counting**

HCT116 cells were planted in 24-well plates with RPMI 1640. Cells were treated with increasing concentration of siRNA and cultured for 48 h, then cells were collected by trypsinization, mixed in PBS and trypan blue added. Cells were counted using a microscope counting chamber.

**Flow cytometric analysis**

At 24 h after transfection, HCT116 cells on 60-mm tissue culture plate were treated with 1 × trypsin-EDTA (Invitrogen, Carlsbad, CA) for 5 min at 37°C; cells were then removed from the plate by gentle scraping, dispersed into cold PBS and washed twice. The cells were resuspended in 1 × binding buffer at a concentration of approximately 1 × $10^6$ cells/mL. Five μL of Annexin V-FITC and 10 μL of PI were added to each cell suspension and incubated at room temperature for 10 min in the dark. The cells were subjected to fluorescence estimation using a FACS Calibur flow cytometer. Uninoculated cells stained with Annexin V-FITC and PI were used to determine background levels of apoptosis.

**Xenograft model**

All animal experiments in this report were performed with approval of the Institutional Animal Care & Use Committee in Ewha Womans University, School of Medicine. The 4-wk-old male BALB/c nude mice were grown in a sanitary room and adjusted for 1 wk before the start of the experiments. Viable HCT116 colon cancer cells ($2.0 \times 10^6$ in PBS/100 μL) were injected subcutaneously into the right flank of the nude mice. Three weeks after tumor cell inoculation with confirmation of successful maturation of tumors, mice were divided randomly into four groups (ten mice per group) and were treated weekly for 4 wk by way of center-intratumoral direct injection at different doses (10, 20, 50 μmol/L) of siRNA manufactured with atelocollagen to achieve effective delivery. To prepare the siRNA/atelocollagen complex, equal volumes of atelocollagen (AteloGene® Systemic Use; Koken, Tokyo, Japan. 0.1% in PBS at pH 7.4) and siRNA solution were combined and mixed by rotation for 20 min at 4°C. In the control group, pure PBS was injected using the same method. The tumors were monitored with a caliper every week over a 4 wk period after siRNA transfection. Tumor volume for each mouse was determined (in cubic millimeter) by measuring in two directions and was calculated as tumor volume = length × (width)$^2$/2. Also, body weight of each mouse was monitored and recorded. Five weeks after the last siRNA injection, all mice were sacrificed according to the animal experimental guidelines and the xenografted tumors were excised and prepared with a routine pathological procedure. Tumor sections were deparaffinized and subjected to Hematoxylin and Eosin staining in the usual manner.

**Statistical analysis**

Each experiment was repeated three times or more. Bands from RT-PCR were quantified with Quantity One software (Bio-Rad, Hercules, CA). mRNA levels were calculated by referring them to the amount of β-actin. The difference between means was performed with analysis of variance. All statistical analyses were performed using SPSS 11.0 software (SPSS, Inc., Chicago, IL). Statistical significance was considered when the $P$ value was less than 0.05.

**RESULTS**

**Transfection of siRNA-Livin to HCT 116 cell line**

To identify whether Livin expression was affected by siRNA, we transfected siRNA at different concentrations (25, 50, 100, 150 and 200 μmol/L) to HCT 116 cell line, and then detected Livin density at 18, 24 and 30 h after transfection by RT-PCR.

Successful transfection of siRNA was detected with fluorescence staining (Figure 1) and expression of Livin gene was compared to β-actin. Control HCT 116 cells expressed Livin very well and this expression was dramatically decreased after siRNA transfection. But this effect was attenuated with time and Livin expression was re-
Livin expression was most effectively suppressed at 25 μmol/L of siRNA, but this suppression was also not dose-dependent (Figure 2).

Reduction of viable cell numbers with siRNA to Livin

First, we estimated cell counts of each group to evaluate tumor cell growth after Livin silencing. We analyzed cultured cells grown in three dishes per group at one time, and repeated this study three times. As seen in Figure 3, the cell count at 18 h after transfection was significantly reduced as compared with control (P < 0.01), but this effect was not time-dependent or dose-dependent. A: Cell count at 18 h post-transfection was significantly reduced as compared with control (P < 0.01); B: Cell count at 24 h post-transfection; C: Cell count at 30 h post-transfection.

Suppression of cellular proliferation by SiRNA

To quantify the cellular viability, MTT assay was performed. The MTT assay showed that, compared with controls, the proliferation of cells transfected with siRNA was remarkably inhibited at 18 h after transfection (P = 0.04), but the inhibitory effect disappeared thereafter, which indicated that the number of viable cells began to increase. There was no significant difference in cellular proliferation depending on siRNA dose (Figure 4).

Induction of apoptosis by SiRNA

Flow cytometric analysis after Annexin V staining was performed to investigate whether Livin-silencing induces apoptosis resulting in reduction of cell count or suppression of cellular proliferation as per the above findings. As a result, the apoptotic rate was increased continuously since 50 μmol/L of siRNA was treated. The apoptotic rate in control was 3.91%, the apoptotic rate of cells transfected with siRNA 50 μmol/L was 30.32%. The apoptotic rates of cells transfected with siRNA 100 μmol/L, 150 μmol/L and 200 μmol/L increased to 32.88%, 36.91% and 45.08%, respectively (Figure 5). The apoptotic rate was increased dose-dependently, but the necrotic portion was also increased. So, it was thought low dose siRNA was more effective in the clinical setting.

Change of tumor volume in vivo after siRNA treatment

Next, we designed a xenograft model to identify the po-
May 28, 2011

Oh BY et al. siRNA therapy in colon cancer

**Figure 4** MTT assay after small interfering RNA transfection in HCT116 cell line. A: The proliferation of cells transfected with siRNA was remarkably inhibited at 18 h post-transfection ($P = 0.04$); B and C: Cellular proliferation at 24 and 30 h post-transfection. The inhibitory effect shown in A disappeared, cellular proliferation was similar with control.

**Figure 5** Results of Annexin V staining after small interfering RNA transfection in HCT116 cell line. The apoptotic portion (right lower quadrant) was increased continuously after siRNA transfection, but the necrotic portion (right upper quadrant) was also increased. A: The apoptotic rate of staining was 0.26%; B: The apoptotic rate of cells transfected with siRNA 150 ($P = 0.04$); B and C: Cellular proliferation at 24 and 30 h post-transfection. The inhibitory effect shown in A disappeared, cellular proliferation was similar with control.

The potential in vivo effects of siRNA on inhibition of the proliferation of colon cancer cells. Viable HCT 116 colon cancer cells were injected subcutaneously into the right flank of the nude mice.

In the first series of experiments, the inoculated mice were divided randomly into four groups of ten mice each and were treated with different doses of siRNA (control, 10, 20 and 50 μmol/L) weekly, for 4 wk. Over a 4 wk period after siRNA injection, the tumor volumes were estimated every week. As seen in Figure 6, the rates of tumor growth significantly decreased in higher than 20 μmol/L transfected groups with siRNA as compared with the control group 2 wk following treatment ($P = 0.03$). However, there was no difference in antitumor effect between 20 μmol/L and 50 μmol/L in the transfected group.

In the first study series, we detected that siRNA 20 μmol/L was the most effective dose for reduction of tumor growth in xenograft models. Thereafter, in the second series of experiments, we divided the inoculated mice randomly into two groups (control group and siRNA 20 μmol/L treated group) of ten mice per group. The mice of the siRNA 20 μmol/L treated group were injected with siRNA daily for 4 wk, and then the tumor volumes were measured every week during that period. The result was similar with the previous experiment; the mean volume of tumors decreased in transfected groups with siRNA.
Oh BY et al., siRNA therapy in colon cancer

Figure 6 Tumor volume after small interfering RNA intratumoral injection in vivo. The inoculated mice were divided into four groups and were treated with different doses of siRNA (10, 20 and 50 µmol/L) weekly for 4 wk; tumor volumes were checked every week. In higher than 20 µmol/L siRNA, the tumor volumes were significantly decreased as compared with control group from 2 wk after transfection (P = 0.03).

20 µmol/L as compared with control groups (Figure 7).

To evaluate the toxic effect of siRNA in vivo, the body weights of mice were taken during the experimental period. The body weight of mice in all groups slightly increased over the entire experimental period; there were no significant body weight changes after siRNA injection compared to the control group. Histologic examination was performed with tissues taken from sacrificed mice after experiment completion. It revealed no significant toxic reaction in kidney, liver and brain of siRNA treated mice compared with the control group (data not shown).

DISCUSSION

Eight human IAP molecules have been reported to date; NAIP (BIRC1), c-IAP1 (BIRC2), c-IAP2 (BIRC3), X-linked IAP (XIAP, BIRC4), Survivin (BIRC5), Apollon (BRUCE, BIRC6), Livin/ML-IAP (BIRC7), and IAP-like protein 2 (BIRC8)[12]. They are categorized as IAP by the presence of a baculovirus IAP repeat (BIR) protein domain, which forms a zinc-fold, a critical motif for regulating apoptosis. Many in this family also harbor a COOH-terminal RING finger domain. The BIR domain constitutes the zinc-fold, which is the important motif in delivering the anti-apoptotic signals[9]. It has been proposed that endogenous Livin has a minor direct effect on caspase activity whereas its anti-apoptotic effect could be ascribed to its antagonizing activity on the XIAP-Smac/DIABLO interaction and has been regarded as counteraction molecules against apoptotic signals[10]. That the IAPs are highly conserved from yeast to mammals suggests the importance of this family in maintaining life[11]. There are numerous reports on overexpression of the IAP family in cancer tissues to normal counterparts. The role of Survivin and Livin, in particular, in carcinogenesis has been well confirmed to date.

Livin was reported in 2001 as a novel IAP family protein[12]. The overactivity of Livin was regarded as a predictor of poor prognosis in cancer patients and a resistance factor to chemotherapeutic agents or radioactive drugs in several cancers[13,14]. The overexpression of Livin mRNA has been found in some tumors including melanoma, breast, cervical, colon and prostate cancers, as well as in lymphoma, in lymphoma and in hepatoma cell lines[15]. Moreover, researchers have shown that only overexpression of Livin-α isoform is correlated with high risk of relapse in bladder cancer[16].

In the previous study, Livin gene was expressed well in the stools of colon cancer patients as opposed to the healthy control group. This finding suggests that the exfoliated cancer cells from the gastrointestinal tumors were contained in the patients’ stool and overexpressed tumor related genes such as Livin were detected from the stool. Based on this result, we chose Livin gene as a treatment target in this experiments.

In recent years, numerous genetic engineering techniques were introduced in drug development markets worldwide such as antisense oligonucleotides, aptamer (single stranded nucleic acids), use of ribozymes, dominant negative mutant construction and siRNA. We focused on siRNA technology because of its target sequence-specific degradation ability and relatively simple application procedure.

In higher organisms, defense mechanisms are more complex but long dsRNAs should not be used as an experimental tool to trigger RNAi in mammalian cells. Long dsRNAs are processed by the endonuclease Dicer.
into short 21 bp duplexes with siRNA instead of direct suppression\[18\]. RNA interference is a post-transcriptional regulation process which exploits a complex pathway that regulates gene expression and includes machinery for sequence specific mRNA degradation\[8,16\].

But there are still some limitations to overcome in applying siRNA in clinical fields. The greatest interference is the short half-life of the delivered siRNA in vivo due to renal clearance. Another is a normally existing RNase activity that can degrade siRNA administrated artificially. The next key to successful in vivo application of siRNA is the delivery system. Transferring the siRNA into target tissues and into the cell cytoplasm is not easily achieved and a most delicate process is required to get the therapeutic potential. Usual methods to achieve maximum therapeutic effects are lipid or protein carriers, liposomes, antibody promoter fusions, cyclodextrin nanoparticles, fusogenic peptides, aptamers, biodegradable polylactide copolymers and polymers\[19\].

There are several reports on siRNA targeting Livin treatments for cancer in the literature. Crnkovic-Mertens et al\[19\] first reported the induction effects of apoptosis with Livin targeted-siRNA in a HeLa cell line. Their results suggested that the possibility of intracellular interference with Livin gene expression sensitized human tumor cells to apoptosis. Recently, Wang et al\[19\] investigated the apoptotic susceptibility of the SGC-7901 gastric cancer cell by shRNA-mediated silencing of the Livin gene. When Livin gene was silenced, the reproductive activity of the gastric cancer cells was significantly lower than the control groups (\(P < 0.05\)). The study also showed that IC50 of 5-FU and cisplatin on gastric cancer cells treated by shRNA decreased and the cells were more susceptible to proapoptotic stimuli (5-FU and cisplatin) (\(P < 0.01\)). In another study\[20\], it was reported that expression of Livin was downregulated by siRNA in dose- and time-dependent manners, and silencing Livin promoted apoptosis in malignant melanoma LiBr cells. They also demonstrated that silencing Livin by siRNA leads to cell cycle arrest at the G0/G1 phase, reducing the rate of DNA synthesis or resulting in apoptosis. With these promising results, a combination treatment of Livin-targeting siRNA with proapoptotic drugs appears to be more effective in clinical perspectives.

In this study, we confirmed that silencing of Livin gene expression with siRNA was well documented in HCT116 colon cancer cells associated with an increased apoptotic response. In preliminary experiments, we tested the expression of Livin immediately, 2, 6, 12 and 24 h after treatment of siRNA (data not shown). The decrease of Livin expression was notable from 2 h after treatment but the effect was not much different before 24 h, so we extended the time to 30 h after treatment of siRNA. Testing dosage was arranged from 25 to 200 \(\mu\)mol/L, but the silencing effect of siRNA was not proportional in order of concentration. It was possible that a very small amount of siRNA could create the action to achieve the silencing of Livin gene in the cell line. Unfortunately, the silencing effect weakened from 24 h after treatment, which means duration of siRNA to Livin is very short and time limited.

Another consideration is the proliferation of the cells not influenced by siRNA affected the total expression of the Livin with time. On the other, the cell count decreased 45% with 25 \(\mu\)mol/L siRNA at 18 h after treatment and lasted for 30 h and cellular proliferation counted by MTT assay revealed the same results with cell counting. Proliferation was more influenced by siRNA treatment in the early phase compared to the decrease of total cell count numbers. With this phenomenon apoptosis increased 24 h after treatment with dose dependent manner. To integrate the full results, silencing of Livin in colon cancer cell was easily achieved with siRNA treatment into the induction of apoptosis from minimal dosage only in in vitro environment.

We used the mouse xenograft model to identify the antitumor effect of siRNA to Livin in vivo. We selected the direct intratumoral injection method to verify the direct effect on tumors. In the clinical setting, it is very difficult to use the infected cells of siRNA before confirmation of drug safety regulation, so direct implication to the human body. Because of the limitation of uptake of siRNA, we adopted atelocollagen in this experiment to obtain maximal therapeutic effects. Atelocollagen is derived from type I collagen of calf dermis by pepsin digestion. A telopeptide that is an amino acid sequence of N- and C-terminal of the collagen contains the most antigenicity. Atelocollagen has limited antigenicity because of a lack of telopeptides, so it is more easily applicable to drug delivery processes. It is well confirmed that atelocollagen-siRNA complexes are taken up into cells to achieve a silencing effects. Also, atelocollagen-siRNA complexes are resistant to nucleases, which is another important advantage in siRNA application in vivo\[19\]. Several reports were found in the database revealing siRNA effects with atelocollagen complex. Atelocollagen is one of the more useful DDS available in clinical settings. Kawata et al\[21\] reported PLK-1 (polo-like kinases-1) siRNA with atelocollagen in hepatic metastatic cells from lung cancer. Takeshita et al\[22\] demonstrated the evidence of tumor targeted delivery of systemically administrated siRNA with atelocollagen, injected siRNA intracardiac to luciferase and luciferase-expressing bone-metastatic tumor models. In another study, a therapeutic effect via atelocollagen-mediated systemic administration of siRNA targeting Bcl-xL into pregrown PC-3 xenografts was reported\[19\].

A number of studies have reported antitumor effects of siRNA in vivo. Verma et al\[23\] demonstrated that siRNA was effective in reducing growth of HCT116 cells in nude mice. These mice were injected with HCT116 cells intraperitoneally and then were treated with siRNA directed against \(\beta\)-catenin, the regulator of cellular proliferation in colon cancer. There was a significant decrease in the tumor size of cells transfected with siRNA directed against \(\beta\)-catenin\[24\]. In another study, it was found that transfected HCT116 colon cancer cells with siRNA against Survivin, a type of IAP family such as Livin, significantly decreased in size as compared with controls in xenograft models\[25\]. In a recent study, it was
May 28, 2011 | Volume 17 | Issue 20 | WJG | www.wjgnet.com

Oh BY et al. siRNA therapy in colon cancer

Figure 8 Hemorrhagic necrosis in small interfering RNA injection site. The inoculated mice were injected with siRNA via the intratumoral route; there was local hemorrhagic necrosis in the direct injection site of siRNA.

observed that siRNA against Survivin remarkably induced apoptosis in SW480 cell as a consequence of the inhibition of Survivin and led to significant inhibition of tumor growth in vivo.

In our xenograft model, the rates of tumor growth were significantly decreased in higher than 20 μmol/L transfected groups with siRNA as compared with control groups. This antitumor effect tended to be greater at a higher dose of siRNA but the differences between each group were not statistically significant. So it would be expected that a low dose of siRNA showed a satisfactory effect on tumor suppression. In addition to the antitumor effect, toxic effects of treatment should be considered. Some therapeutics have been associated with toxic side effects such as weight loss and other organ injury. These systemic toxicities may be related with higher morbidity and lower response rate, resulting in poorer survival. Thus, if there are systemic toxicities caused by drugs, no matter how effective, they should not be used. In this study, measured body weights of mice had no differences, and there were no significant pathologic findings on tissues withdrawn from siRNA-treated group. For these reasons, it could be thought that siRNA targeting Livin can be used in colon cancer therapy without systemic toxic effects in vivo. In our present study, another interesting finding was detected despite an effective reduction of tumor size with siRNA. Local hemorrhagic necrosis was seen in the intratumoral injection site of siRNA with syringe, this finding was not identified in other studies (Figure 8). If there are local side effects such as this, even though there is no evidence of systemic toxicity of siRNA, we should carefully determine administration routes to develop antitumor treatments using siRNA.

In conclusion, siRNA-mediated downregulation of Livin expression can induce apoptosis in colon cancer in vitro and in vivo, which implies new potential cancer therapeutics using siRNA in colon cancer.

REFERENCES
1 Shen W, Wang CY, Wang XH, Fu ZX. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009; 28: 81
2 Zhang L, Fogg DK, Waisman DM. RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells. J Biol Chem 2004; 279: 2053-2062
3 Lv W, Zhang C, Hao J. RNAi technology: a revolutionary tool for the colorectal cancer therapeutics. World J Gastroenterol 2006; 12: 4636-4639
4 Yang L, Kang WK. The effect of HIF-1alpha siRNA on growth and chemosensitivity of MIA-paca cell line. Yonsei Med J 2008; 49: 295-300
5 Li TJ, Song JN, Kang K, Tong SS, Hu ZL, He TC, Zhang BQ, Zhang CQ. RNA interference-mediated gene silencing of vascular endothelial growth factor in colon cancer cells. World J Gastroenterol 2007; 13: 5312-5316
6 Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005; 12: 5-11
7 Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncoreg non gene small interfering RNA. Cancer Res 2006; 66: 9736-9743
8 Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci 2006; 97: 689-696
9 Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-3246
10 Liu B, Han M, Wen JK, Wang L. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 2007; 250: 168-176
11 Wang L, Zhang Q, Liu B, Han M, Shan B. Challenge and promise: roles for Livin in progression and therapy of cancer. Mol Cancer Ther 2008; 7: 3661-3669
12 Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli

COMMENTS

Background
Colon cancer is one of the most common malignancies and has increased in incidence in recent years. Several treatment modalities have been used, especially in metastatic diseases. Several studies have been reported to implicate gene therapy for metastatic colon cancer. Livin, a type of inhibitor of apoptosis, protects cells from various proapoptotic stimuli. So Livin is an effective target for colorectal cancer treatment.

Research frontiers
The overexpression of Livin has been reported in colorectal cancer. However, the direct tumor regression effect of Livin silencing has not been unequivocally addressed. In this study, the authors investigate the effect of silencing Livin gene expression with siRNA to apoptosis and proliferation in colon cancer cell line.

Innovations and breakthroughs
There are several reports on siRNA targeting Livin treatments for cancer. But these studies were nearly all performed in vitro and there were few studies about colorectal cancer. In this study, the authors confirmed that silencing of Livin gene expression with siRNA was well documented in vitro and in vivo, especially in colorectal cancer.

Applications
siRNA-mediated downregulation of Livin expression can induce apoptosis in colon cancer in vitro and in vivo, which may imply new potential cancer therapeutics using siRNA in colorectal cancer.

Terminology
Livin is a 280 amino acid-protein and a member of the mammalian type of inhibitor of apoptosis. It inhibits apoptosis by binding to caspase 3, caspase 7 and caspase 9. Its overexpression protects cells from various proapoptotic stimuli, and is shown in numerous cancers. RNA interference is a fundamental protective process in eukaryotic cells, which is able to block harmful signals by targeting complementary mRNA and cleaving it. The role of RNAi is supposed to be a defense mechanism against deleterious genomic instability.

Peer review
The experiments are properly performed, and findings support their conclusion.
M, Coggi G, Bosari S. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009; 9: 125

13 Wang R, Lin F, Wang X, Gao P, Dong K, Zou AM, Cheng SY, Wei SH, Zhang HZ. Silencing Livin gene expression to inhibit proliferation and enhance chemosensitivity in tumor cells. Cancer Gene Ther 2008; 15: 402-412

14 Crnković-Mertens I, Muley T, Meister M, Hartenstein B, Semzow J, Butz K, Hoppe-Seyler F. The anti-apoptotic livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells. Lung Cancer 2006; 54: 135-142

15 Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006; 13: 644-670

16 Verdel A, Vavasseur A, Le Gorrec M, Touat-Todeschini L. Common themes in siRNA-mediated epigenetic silencing pathways. Int J Dev Biol 2009; 53: 245-257

17 Mu P, Nagahara S, Makita N, Tarumi Y, Kadmatsu K, Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 2009; 125: 2978-2990

18 Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 2003; 22: 8330-8336

19 Wang TS, Ding QQ, Guo RH, Shen H, Sun J, Lu KH, You SH, Ge HM, Shu YQ, Liu P. Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed Pharmacother 2010; 64: 333-338

20 Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008; 68: 1247-1250

21 Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi M, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther 2008; 7: 2904-2912

22 Takeshita F, Minakuchi Y, Nagahara S, Homma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-12182

23 Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9: 1291-1300

24 Williams NS, Gaynor RB, Scoogg S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9: 931-946